Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
October 22, 2025Pamplona/MadridIn recruitment
NOVOFFOX Trial of tumor treatment fields (TTFields, 150 kHz) concomitant with modFOLFIRINOX for first-line treatment of metastatic pancreatic adenocarcinoma (NOVOFFOX).
The objective of this study is to evaluate the efficacy and safety of TTFields together with the chemotherapy you are going to receive for your cancer (oxaliplatin-irinotecan-fluorouracil, FOLFIRINOX). -
October 22, 2025Pamplona/MadridIn recruitment
-
October 22, 2025Pamplona/MadridIn recruitmentEarly phase
-
October 20, 2025Pamplona/MadridIn recruitment
-
October 20, 2025Pamplona/MadridIn recruitmentEarly phase
IMGN853-0425 Clinical Trial - Randomized, open-label, phase 2 study of mirvetuximab soravtansine in patients with epithelial ovarian, primary peritoneal and fallopian tube cancer.
The main objective of this study is to investigate the efficacy and safety profile of MIRV with an alternative administration schedule to the approved U.S. schedule, with the aim of potentially improving the risk-benefit profile. In addition, a starting dose of MIRV will be determined in patients with moderate hepatic impairment. -
October 15, 2025PamplonaIn recruitmentEarly phase
-
October 15, 2025PamplonaIn recruitmentEarly phase
-
October 15, 2025MadridIn recruitmentEarly phase
-
October 14, 2025MadridIn recruitmentEarly phase
MK-1022-010 Phase 2 clinical trial to evaluate patritumab deruxtecan pembrolizumab in high-risk triple-negative breast cancer
The main objective is to determine whether the combination of patritumab deruxtecan and pembrolizumab administered before or after chemotherapy is more effective and safer compared to the standard combination of pembrolizumab and chemotherapy followed by surgery and adjuvant treatment with pembrolizumab, in order to improve the disease-free survival rate and other clinical indicators in patients with triple-negative breast cancer. -
October 6, 2025Pamplona/MadridIn recruitment
1479-0012 Clinical trial to find an appropriate dose of zongertinib in combination with trastuzumab deruxtecan or trastuzumab emtansine, and to test whether it helps people with different types of HER2 cancer that has spread
The primary objective is to characterize the safety, tolerability and dose-toxicity curve of zongertinib in combination with T-DXd or in combination with T-DM1 in patients with HER2 metastatic breast cancer (mBC) or metastatic gastric or gastroesophageal adenocarcinoma (mGEAC) by evaluating escalating dose levels with overdose monitoring to achieve the primary objective of determining maximum tolerated doses (MTDs) and/or doses for future development.